BLOOD COAGULATION & FIBRINOLYSIS

Scope & Guideline

Connecting Researchers to the Future of Blood Science

Introduction

Welcome to the BLOOD COAGULATION & FIBRINOLYSIS information hub, where our guidelines provide a wealth of knowledge about the journal’s focus and academic contributions. This page includes an extensive look at the aims and scope of BLOOD COAGULATION & FIBRINOLYSIS, highlighting trending and emerging areas of study. We also examine declining topics to offer insight into academic interest shifts. Our curated list of highly cited topics and recent publications is part of our effort to guide scholars, using these guidelines to stay ahead in their research endeavors.
LanguageEnglish
ISSN0957-5235
PublisherLIPPINCOTT WILLIAMS & WILKINS
Support Open AccessNo
CountryUnited States
TypeJournal
Convergefrom 1990 to 2024
AbbreviationBLOOD COAGUL FIBRIN / Blood Coagul. Fibrinolysis
Frequency8 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressTWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103

Aims and Scopes

The journal 'Blood Coagulation & Fibrinolysis' focuses on a wide range of topics related to hemostasis, thrombosis, and bleeding disorders. It aims to disseminate cutting-edge research findings that contribute to the understanding and management of coagulation disorders, with a strong emphasis on clinical implications and biochemical mechanisms.
  1. Coagulation Disorders and Thrombosis:
    The journal covers various aspects of coagulation disorders, including inherited and acquired thrombophilias, immune thrombocytopenic purpura, and other thrombotic conditions, focusing on their pathophysiology, diagnosis, and management.
  2. Clinical Outcomes and Treatment Strategies:
    Research published in the journal often explores clinical outcomes associated with different treatment modalities, including novel therapies for hemophilia, anticoagulation strategies, and the effectiveness of new drugs.
  3. Laboratory Diagnostics and Methodologies:
    A significant part of the journal is dedicated to advancements in laboratory diagnostics, including the evaluation of coagulation assays, thromboelastometry, and the development of new diagnostic techniques for bleeding disorders.
  4. Genetic and Molecular Studies:
    The journal also emphasizes genetic studies related to coagulation factors and their mutations, providing insights into the molecular basis of bleeding disorders and potential therapeutic targets.
  5. Epidemiological Studies:
    Epidemiological research focusing on the prevalence, risk factors, and socio-economic impact of coagulation disorders is a key area of interest, contributing to the understanding of these conditions at a population level.
The journal has shown an evolving focus on several emerging themes that reflect current trends in hematology and coagulation research. These themes indicate the journal's responsiveness to new challenges and advancements in the field.
  1. Impact of COVID-19 on Coagulation:
    Research investigating the effects of COVID-19 on coagulation and thrombotic risk has surged, reflecting the pandemic's significant impact on health and its implications for patients with pre-existing coagulation disorders.
  2. Innovative Therapies and Treatments:
    There is an increasing number of studies focusing on innovative therapies for treating thrombotic and bleeding disorders, including targeted therapies and novel agents like caplacizumab and emicizumab.
  3. Real-World Evidence and Outcomes Research:
    The journal is increasingly publishing studies that provide real-world evidence regarding treatment outcomes, emphasizing the importance of clinical effectiveness data in everyday practice.
  4. Integration of Genetic Testing in Management:
    Emerging themes include the integration of genetic testing into the management of coagulation disorders, highlighting the growing importance of personalized medicine in this field.
  5. Interdisciplinary Approaches to Hemostasis:
    There is a trend towards interdisciplinary research that incorporates insights from immunology, oncology, and infectious diseases, reflecting the complex interactions between coagulation and other bodily systems.

Declining or Waning

While the journal maintains a broad focus, certain themes appear to be declining in prominence based on recent publications. This may reflect shifts in research priorities or advancements in understanding that reduce the need for certain types of studies.
  1. Traditional Anticoagulation Therapies:
    There has been a noticeable decrease in studies solely focused on traditional anticoagulation therapies such as warfarin, as newer direct oral anticoagulants gain prominence and become the focus of research.
  2. Case Reports of Rare Disorders:
    The frequency of case reports detailing rare coagulation disorders seems to be waning, possibly due to a shift towards more comprehensive studies that aggregate data across multiple cases rather than focusing on singular instances.
  3. Basic Science Studies:
    Basic science studies that explore fundamental mechanisms of coagulation without direct clinical applications are appearing less frequently, as the journal pivots towards research with immediate clinical relevance.
  4. Historical Perspectives on Coagulation Disorders:
    There is a decline in publications that address historical perspectives or traditional views on coagulation disorders, indicating a shift towards contemporary and evidence-based practices.

Similar Journals

Egyptian Journal of Haematology

Shaping the Landscape of Hematology in the Middle East
Publisher: WOLTERS KLUWER MEDKNOW PUBLICATIONSISSN: 1110-1067Frequency: 4 issues/year

The Egyptian Journal of Haematology, published by WOLTERS KLUWER MEDKNOW PUBLICATIONS, stands as a pivotal resource in the field of hematology, particularly within the context of Egypt and the broader Middle Eastern region. This journal is dedicated to disseminating high-quality research that explores the latest advancements in blood disorders, hematologic malignancies, and transfusion medicine. With a focus on original research, case studies, and reviews, it aims to provide a comprehensive platform for hematologists, researchers, and healthcare professionals to enhance their understanding and management of hematological conditions. Although it is not an open-access journal, the rigorous peer-review process ensures that only the most impactful studies are published, contributing to the journal's reputation in the academic community. The Egyptian Journal of Haematology serves as an essential tool for advancing knowledge, improving clinical outcomes, and fostering collaboration among experts in the field.

Iraqi Journal of Hematology

Elevating Knowledge, Elevating Care
Publisher: WOLTERS KLUWER MEDKNOW PUBLICATIONSISSN: 2072-8069Frequency: 2 issues/year

Iraqi Journal of Hematology is a prominent peer-reviewed open-access journal dedicated to advancing the field of hematology. Published by Wolters Kluwer Medknow Publications, this journal provides a platform for researchers, professionals, and students to share cutting-edge findings and developments in various aspects of hematology, including blood diseases, diagnostics, and innovative treatments. Since its transition to open access in 2016, the journal has significantly increased its reach, allowing for wider dissemination of critical research to a global audience. With an ISSN of 2072-8069 and an E-ISSN of 2543-2702, the Iraqi Journal of Hematology strives to adhere to the highest scholarly standards and plays a vital role in the ongoing discourse in hematological research. Researchers are encouraged to contribute to this essential resource for the scientific community, contributing to the advancement of knowledge that ultimately improves patient care and treatment outcomes.

THROMBOSIS AND HAEMOSTASIS

Transforming Understanding of Hematological Disorders
Publisher: GEORG THIEME VERLAG KGISSN: 0340-6245Frequency: 12 issues/year

THROMBOSIS AND HAEMOSTASIS is a prestigious journal published by GEORG THIEME VERLAG KG, dedicated to advanced research in the field of hematology. With an esteemed Impact Factor and recognized as Q1 in its category for 2023, the journal is regarded for its pivotal role in disseminating significant findings that contribute to our understanding of thrombosis and hemostasis. Since its inception in 1976, this journal has continuously published cutting-edge studies and reviews, making it a vital resource for researchers, healthcare professionals, and students alike. The journal’s commitment to high-quality research is reflected in its impressive Scopus Ranking of #18 out of 137 in Medicine - Hematology, placing it in the 87th percentile among its peers. Although not currently open access, THROMBOSIS AND HAEMOSTASIS remains an authoritative source for exploring novel therapeutic strategies and the latest scientific advancements in the field. Based in Stuttgart, Germany, this journal serves as a critical platform for sharing knowledge and fostering collaboration within the global hematology community.

BLOOD

Shaping the Future of Hematological Discovery.
Publisher: AMER SOC HEMATOLOGYISSN: 0006-4971Frequency: 52 issues/year

BLOOD, published by the American Society of Hematology, is a premier peer-reviewed journal in the fields of Biochemistry, Cell Biology, Hematology, and Immunology. With an impressive impact factor and ranking in the top quartiles (Q1) across multiple disciplines, BLOOD is essential reading for researchers and professionals seeking to stay updated on the latest advancements in hematology and related fields. The journal has been a cornerstone of hematological research since its inception in 1946, providing a platform for rigorous scientific inquiry and discourse. Its commitment to publishing high-quality original research, comprehensive reviews, and insightful editorials makes it a vital resource for students, practitioners, and scientists alike. By offering exceptional access to influential publications, BLOOD continues to shape the future of hematology and enhance understanding of blood-related disorders, marking its vital role in advancing both basic and clinical research.

PLATELETS

Innovating hematology through groundbreaking research.
Publisher: TAYLOR & FRANCIS INCISSN: 0953-7104Frequency: 8 issues/year

PLATELETS is a distinguished journal published by Taylor & Francis Inc that has been at the forefront of research in the fields of hematology and medicine since its inception in 1990. With an ISSN of 0953-7104 and an E-ISSN of 1369-1635, this journal boasts a solid reputation, as reflected by its Q2 ranking in both Hematology and Miscellaneous Medicine categories in 2023. PLATELETS serves as an essential platform for disseminating pioneering research, reviews, and case studies related to platelet biology, thrombosis, hemostasis, and their clinical implications. Although not an open-access publication, it is indexed in reputable databases, ensuring visibility and citation of quality contributions. Researchers, clinicians, and students alike will find valuable insights that may inform their work and enhance their understanding of the crucial role of platelets in health and disease. This journal's commitment to advancing knowledge and fostering innovation makes it a pivotal resource in the academic community.

Journal of Blood Medicine

Exploring Frontiers: Where Blood Medicine Meets Cutting-edge Science
Publisher: DOVE MEDICAL PRESS LTDISSN: 1179-2736Frequency: 1 issue/year

The Journal of Blood Medicine, published by DOVE MEDICAL PRESS LTD, stands as a vital resource in the field of hematology, focusing on the latest research developments and clinical advancements in blood medicine. With an impact factor reflective of its growing relevance, this open-access journal has been delivering quality scholarly work since 2010, ensuring that critical research is readily available to the global scientific community. The journal operates under an open-access model, further enhancing its dissemination and accessibility to researchers, professionals, and students alike. In the 2023 rankings, it secured a Q3 category status within hematology and achieved a commendable 76th rank out of 137 in Scopus listings, indicating its commitment to quality and innovation in this specialized area. Located in New Zealand, the journal's diverse topics encompass clinical research, treatment modalities, and emerging therapies, contributing significant insights vital for shaping future advancements in blood medicine.

CURRENT OPINION IN HEMATOLOGY

Connecting groundbreaking research to clinical practice.
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 1065-6251Frequency: 6 issues/year

CURRENT OPINION IN HEMATOLOGY is a leading peer-reviewed journal published by Lippincott Williams & Wilkins, focusing on the latest advancements and insights in the field of hematology. With an impressive impact factor and ranked in the first quartile (Q1) of its category, this journal serves as a vital resource for researchers, clinicians, and students seeking to stay informed on contemporary issues and emerging trends in hematological research and treatment. Established in 1994, it showcases critical reviews, expert commentary, and systematic analyses across a broad spectrum of hematology topics, contributing significantly to clinical and experimental knowledge through its robust editorial standards. While offering traditional subscription access, CURRENT OPINION IN HEMATOLOGY remains committed to providing a platform that bridges the gap between fundamental research and clinical application, making it indispensable for professionals dedicated to advancing patient care and scientific understanding in hematology.

Research and Practice in Thrombosis and Haemostasis

Innovating hematology through open-access insights.
Publisher: ELSEVIERISSN: Frequency: 8 issues/year

Research and Practice in Thrombosis and Haemostasis, published by Elsevier, is a prominent open-access journal dedicated to advancing the field of hematology through high-quality research and clinical practice. Since its inception in 2017, this journal has established itself as a vital resource for researchers, healthcare professionals, and students interested in thrombosis and hemorrhage management, showcasing original research, reviews, and clinical studies. The journal’s commitment to accessible knowledge is reflected in its open-access model, allowing researchers worldwide to share their findings without financial barriers. With an impressive 2023 Scopus rank of #42 out of 137 in the hematology category and a respectable Q2 classification, it provides an authoritative platform for innovative ideas and cutting-edge developments in the field. As the journal continues to grow in stature, it aims to foster collaboration and knowledge exchange amongst professionals dedicated to improving patient outcomes in thrombosis and hemostasis.

JOURNAL OF THROMBOSIS AND THROMBOLYSIS

Elevating discourse in cardiovascular medicine.
Publisher: SPRINGERISSN: 0929-5305Frequency: 8 issues/year

JOURNAL OF THROMBOSIS AND THROMBOLYSIS, published by Springer in the Netherlands, serves as a vital platform for research in the fields of Cardiology and Cardiovascular Medicine and Hematology. With an impressive impact factor, this journal ranks in the Q2 category for both fields according to the latest metrics, evidencing its significant influence and contribution to ongoing scholarly discourse. Spanning over three decades from 1994 to 2024, the journal provides an essential source for innovative studies, clinical practices, and comprehensive reviews related to thrombosis and thrombolysis. Researchers, clinicians, and students alike will find valuable insights and cutting-edge knowledge that address the complexities of blood coagulation and its implications in cardiovascular health. The journal is indexed in Scopus, with commendable rankings, further establishing its reputation in the academic community.

BLOOD REVIEWS

Elevating knowledge in blood disorders and cancer care.
Publisher: CHURCHILL LIVINGSTONEISSN: 0268-960XFrequency: 6 issues/year

BLOOD REVIEWS is a highly regarded journal published by Churchill Livingstone, specializing in the fields of Hematology and Oncology. With an impressive Q1 ranking in both disciplines and placing in the top 10% of its peer categories according to Scopus metrics, it provides an essential platform for the dissemination of cutting-edge research and reviews pertaining to blood disorders and cancer treatment. Since its inception in 1987 and continuing through 2024, the journal has established itself as a cornerstone for healthcare professionals, researchers, and students who seek to advance their understanding of hematologic and oncologic topics. While not an open-access journal, BLOOD REVIEWS retains a reputation for delivering high-quality, peer-reviewed articles that foster dialogue and innovation within the scientific community. For those in the United States and beyond, the journal serves as a vital resource, housed at the Journal Production Department in Edinburgh, Scotland, ensuring accessibility and a global reach in its critical academic contributions.